Skip to content
Menu

Morgan Stanley Maintains Overweight on Monopar Therapeutics, Raises Price Target to $133

Benzinga Newsdesk 19 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.

Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.

Read at benzinga.com